Skip to content

Transcutaneous vagus nerve stimulation to enhance exposure efficacy in public speaking anxiety

Transcutaneous vagus nerve stimulation to enhance exposure efficacy in public speaking anxiety - tvNS and exposure for public speaking anxiety

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49420
Enrollment
52
Registered
2019-05-29
Start date
2020-04-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

public speaking anxiety

Interventions

All participants receive two standardized sessions of exposure for SAD, 26 randomly allocated participants will receive tVNS during the first session, 26 will receive sham stimulation during the fir

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: A. Between 18-70 years old B. Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear C. Self reported SAD symptoms above clinical cut-off (score > 30 on the LSAS).

Exclusion criteria

Exclusion criteria: A. Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient*s report of receiving specific and regular exposure assignments as part of previous therapy. B. Prior participation in tVNS research C. Entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where SAD is not judged to be the predominant disorder, participants will not be eligible. D. Psychosis or delusion disorders (current or in the past) E. Patients with significant suicidal ideations or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from participation and referred for appropriate clinical intervention. F. Mental retardation G. (History of) Substance or alcohol dependence H. Somatic illness I. Pregnancy or lactation J. Antipsychotic medication K. Participants that use antidepressants or benzodiazepines will not be excluded, but have to be on a stable dose for at least 6 weeks prior to enrollment. L. Insufficient ability to speak and write Dutch

Design outcomes

Primary

MeasureTime frame
Subjective Units of Distress (SUDs): participants will provide fear ratings (ranging from 0; no fear to 100 most anxiety imaginable) prior, during and after both exposure sessions. Main outcome is the change of the SUDs during the first exposure session.

Secondary

MeasureTime frame
Secondary outcome measures: - SUDs ratings during the second exposure session, i.e. retention of extinction memory - Self-reported social anxiety (Social Phobia Scale) - Cardiac activity (Heart Rate Variability; HRV) - Harm Expectancies

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)